ArticlePloS one2017
Liver X receptor activation promotes differentiation of regulatory T cells.
Article in PloS one, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 49 citations in OpenAlex.
- Liver X receptor: A potential target for inflammatory bowel disease and colorectal cancer (Review).Molecular medicine reports · 2026Review
- Lipid Metabolism in Regulatory T Cells in Health and Disease.Journal of inflammation research · 2026Review
- Relationships Between Circulating Lipids, Lipoproteins, and Lymphocyte Subsets in the Multi-Ethnic Study of Atherosclerosis.Global heart · 2026Article
- Fatty acid metabolism-an emerging regulatory node in T-cell immunometabolism.Clinical & translational immunology · 2026Review
- Article
- Altered Lipid Metabolism in CNS Demyelination and Remyelination Are Key Elements Driving Progressive MS.International journal of molecular sciences · 2025Review
- Dysregulated lipid metabolism networks modulate T-cell function in people with relapsing-remitting multiple sclerosis.Clinical and experimental immunology · 2024Article
- Research progress on the mechanism of cholesterol-25-hydroxylase in intestinal immunity.Frontiers in immunology · 2023Review
- NR1H3 (LXRα) is associated with pro-inflammatory macrophages, predicts survival and suggests potential therapeutic rationales in diffuse large b-cell lymphoma.Hematological oncology · 2022Article
- PPAR-α Agonist Fenofibrate Ameliorates Sjögren Syndrome-Like Dacryoadenitis by Modulating Th1/Th17 and Treg Cell Responses in NOD Mice.Investigative ophthalmology & visual science · 2022Article
- Cholesterol metabolism: a new molecular switch to control inflammation.Clinical science (London, England : 1979) · 2021Review
- LXR directly regulates glycosphingolipid synthesis and affects human CD4+ T cell function.Proceedings of the National Academy of Sciences of the United States of America · 2021Article
- Liver X receptor regulates Th17 and RORγtMucosal immunology · 2021Article
- Disrupted Lipid Metabolism in Multiple Sclerosis: A Role for Liver X Receptors?Frontiers in endocrinology · 2021Review
- Transcriptional Regulation of Metabolic Pathways via Lipid-Sensing Nuclear Receptors PPARs, FXR, and LXR in NASH.Cellular and molecular gastroenterology and hepatology · 2021Review
- Myeloid-Derived Suppressive Cells Deficient in Liver X Receptor α Protected From Autoimmune Hepatitis.Frontiers in immunology · 2021Article
- Diverse Immunoregulatory Roles of Oxysterols-The Oxidized Cholesterol Metabolites.Metabolites · 2020Review
- T-cell regulation of fibroblasts and cardiac fibrosis.Matrix biology : journal of the International Society for Matrix Biology · 2020Review
- Metabolic signaling in T cells.Cell research · 2020Review
- Metabolic Optimisation of Regulatory T Cells in Transplantation.Frontiers in immunology · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The nuclear receptor Liver X Receptor (LXR) is a ligand-activated transcription factor that has been implicated in control of chronic inflammation by downregulating pro-inflammatory T cell responses. An impaired function of regulatory T cells, a subset of CD4+ T cells with a crucial role in maintaining lymphocytes homeostasis and immune regulation, is frequently observed in chronic inflammatory diseases. We observed that pharmacological activation of LXR in T cells not only resulted in a thorough suppression of Th1 and Th17 polarization in vitro, but also significantly induced regulatory T cells (Treg) cell differentiation in a receptor-specific fashion. In line with this, systemic LXR activation by oral treatment of mice with the LXR agonist GW3965 induced gut-associated regulatory T cells in vivo. Importantly, such LXR-activated Tregs had a higher suppressive capacity in functional in vitro coculture assays with effector T cells. Our data thus point towards a dual role of LXR-mediated control of inflammation by suppression of pro-inflammatory T cells and reciprocal induction of regulatory T cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.